AnaptysBio, Inc. (NASDAQ:ANAB) Receives $35.11 Consensus Price Target from Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been given an average recommendation of “Moderate Buy” by the eleven research firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $35.11.

Several equities analysts have issued reports on the stock. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research note on Monday, March 3rd. Wedbush reiterated an “outperform” rating and issued a $40.00 price target on shares of AnaptysBio in a research report on Wednesday, February 12th. Wells Fargo & Company increased their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. HC Wainwright restated a “neutral” rating and issued a $22.00 price target on shares of AnaptysBio in a research report on Tuesday, March 4th. Finally, Truist Financial dropped their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th.

Insider Activity at AnaptysBio

In other news, Director Ecor1 Capital, Llc acquired 6,646 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was purchased at an average cost of $12.95 per share, with a total value of $86,065.70. Following the purchase, the director now directly owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

A number of institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in shares of AnaptysBio by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company’s stock worth $880,000 after buying an additional 528 shares during the last quarter. California State Teachers Retirement System raised its position in AnaptysBio by 10.3% during the fourth quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 1,359 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of AnaptysBio by 5.5% in the fourth quarter. Woodline Partners LP now owns 485,073 shares of the biotechnology company’s stock valued at $6,422,000 after purchasing an additional 25,094 shares in the last quarter. Soleus Capital Management L.P. acquired a new stake in shares of AnaptysBio in the fourth quarter valued at approximately $5,481,000. Finally, Squarepoint Ops LLC increased its stake in shares of AnaptysBio by 81.7% during the 4th quarter. Squarepoint Ops LLC now owns 80,870 shares of the biotechnology company’s stock worth $1,071,000 after purchasing an additional 36,365 shares in the last quarter.

AnaptysBio Stock Up 1.6 %

ANAB stock opened at $18.95 on Friday. The business has a 50 day moving average price of $17.14 and a 200 day moving average price of $22.05. The stock has a market cap of $581.14 million, a price-to-earnings ratio of -3.12 and a beta of 0.02. AnaptysBio has a fifty-two week low of $12.21 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($1.61) by $0.89. The business had revenue of $43.11 million during the quarter, compared to the consensus estimate of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, sell-side analysts anticipate that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has initiated a share buyback plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.